The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.

PHASE3CompletedINTERVENTIONAL

Enrollment

137

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

April 24, 2024

Conditions

Advanced Prostate Cancer

Interventions

DRUG

Leuprolide Injectable Emulsion (CAMCEVI®)

Leuprolide Injectable Emulsion (CAMCEVI®)，Subcutaneous injection，Once every 24 weeks for a total of 2 doses

Trial Locations (1)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY